164
Pfizer announced that it sold nearly $ 8 billion in doses of the Covid vaccine in the second quarter, raising its 2021 sales estimates to $ 33.5 billion (up from the previous 26).
The pharmaceutical company therefore continues its path in the growth segment, also favored by the unpleasant spread of the Delta variant and by the opportunity debated by scientists to carry out a further booster to increase immunity in already vaccinated subjects.
Pfizer’s results even exceeded Wall Street’s expectations. Earnings per share reached $ 1.07 against the expected 0.97, while revenues reached $ 18.98 billion, exceeding the estimated 18.74.